Install
FirstWord
- 112articles · 30d
- 11+ hour agolatest article
- Aug 17, 2026earliest in window
- 0%with images
- 13avg words
- Medical 92
- Health 75
- Health & Wellness 68
- Business & Industrial 39
- Economy, Business & Finance 25
- Finance & Business 16
- Science & Technology 10
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
AstraZeneca's oral SERD stumbles in Phase III first-line breast cancer trial
1+ day, 3+ hour ago (12+ words) firstwordpharma.com...
AbbVie aims to expand Qulipta's label into new migraine market
3+ day, 10+ hour ago (12+ words) FirstWord PHARMA...
Animal data trigger enrollment pause in Biohaven's epilepsy study
3+ day, 14+ hour ago (11+ words) FirstWord PHARMA...
NodThera rebrands as Rezera, charts registrational path for PAD drug
4+ day, 3+ hour ago (12+ words) FirstWord Pharma...
Encoded pulls in $275M for pivotal study of Dravet gene therapy
4+ day, 11+ hour ago (13+ words) FirstWord PHARMA...
Kura spins out Caspian to take menin inhibitor into diabetes
4+ day, 22+ hour ago (12+ words) FirstWord Pharma...
Acting heads of FDA centres land permanent gigs, plus new AI leader
5+ day, 9+ hour ago (14+ words) FirstWord Pharma...
Pharvaris' oral HAE hopeful significantly cuts attacks in pivotal study
5+ day, 15+ hour ago (12+ words) FirstWord PHARMA...
Moonwalk unveils gene silencing approach to obesity, $70M in fresh funds
5+ day, 21+ hour ago (13+ words) FirstWord Pharma...
Novartis??? Avidity-sourced del-desiran stumbles in Phase III myotonic dystrophy study
6+ day, 2+ hour ago (12+ words) Novartis’ Avidity-sourced del-desiran stumbles in Phase III myotonic dystrophy study FirstWord Pharma...